Skip to main content
main-content

07.01.2016 | Original Article | Ausgabe 7/2016

Tumor Biology 7/2016

Decreased CK1δ expression predicts prolonged survival in colorectal cancer patients

Zeitschrift:
Tumor Biology > Ausgabe 7/2016
Autoren:
Julia Richter, Steven Rudeck, Anna-Laura Kretz, Klaus Kramer, Steffen Just, Doris Henne-Bruns, Andreas Hillenbrand, Frank Leithäuser, Johannes Lemke, Uwe Knippschild
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s13277-015-4745-8) contains supplementary material, which is available to authorized users.
Johannes Lemke and Uwe Knippschild shared senior authorship of this article.
Julia Richter and Steven Rudeck contributed equally to this work.

Abstract

Cancers arising from the large intestine or rectum are called colorectal cancer (CRC) and represent the fourth leading cause of cancer-related death worldwide. Since casein kinase 1 (CK1) isoforms are involved in many cellular processes and have been reported to be deregulated in various tumor entities, CK1 has become an interesting drug target. In this study, we examined the potential of CK1δ expression levels in tumor tissue of CRC patients as a prognostic biomarker. We show by quantitative RNA expression analyses that decreased CK1δ expression levels in tumor tissue predict prolonged survival rates. Random sampling of CK1δ stained tumor tissue indicates that CK1δ gene expression corresponds with CK1δ protein expression. Especially in low grade (grade 1, grade 2) and in UICC II/III classified tumors decreased CK1δ RNA levels correlate with significantly improved survival rates when the tumor was located in the right colon. We furthermore found gender-specific differences within these subgroups, revealing most significant increase in overall survival rates in male patients with tumors in right colon expressing low levels of CK1δ RNA. Results become even clearer, when only male patients over 50 years were considered. Together, these findings support the assumption that CK1δ might be a prognostic biomarker for CRC thereby providing an interesting drug target for the development of new therapy concepts.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
ESM 1 (PDF 691 kb)
13277_2015_4745_MOESM1_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 7/2016

Tumor Biology 7/2016 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.